Regeneron Pharmaceuticals

Cyrus Biotechnology’s COVID therapeutic lead, ACE2.v2.4, strongly binds and neutralizes SARS-CoV-2 omicron variant potentially providing long term protection

Retrieved on: 
Monday, December 27, 2021
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Diamond, Microbiology, Omicron, Hoshino, Biophysics, University of Washington Department of Bioengineering, VOC, Volatile organic compound, Engineering, ACE2, Biotechnology, WRF, Industry, University, Protein, Solubility, Discovery, Therapy, COVID-19, Regeneron Pharmaceuticals, Software, Associate, Science Advances, COVID, Company, Antibody, Safety, Severe acute respiratory syndrome coronavirus 2, Vaccine, Champaign County, Illinois, Research, Multimedia, AI, SARS-COV-2, Pharmaceutical industry, ISelect

ACE2.v2.4 was engineered to bind to future variants of the virus, providing a therapeutic for COVID for years to come, and these data demonstrate that molecule is capable of providing superior protection against novel variants.

Key Points: 
  • ACE2.v2.4 was engineered to bind to future variants of the virus, providing a therapeutic for COVID for years to come, and these data demonstrate that molecule is capable of providing superior protection against novel variants.
  • In contrast, new work, performed at Cyrus and the University of Illinois, now shows that ACE2.v2.4 retains nearly all of its efficacy against omicron.
  • ACE2.v2.4 has already been shown to tightly bind every VOC in cell-based assays and to neutralize the original virus in mouse studies.
  • Recently released pseudovirus neutralization studies from the Hoshino laboratory in Kyoto confirms that Cyruss ACE2.v2.4 (and other Cyrus variants) successfully neutralize omicron.

Alnylam Comments on FDA Approval of Leqvio®, the First siRNA (RNAi Therapeutic) Approved to Reduce LDL-C

Retrieved on: 
Wednesday, December 22, 2021
FDA, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Mortality, Sequah Medicine Company, Nobel Prize, Disease, Lists of diseases, LinkedIn, Cell, CNS, Twitter, Sirna, Private Securities Litigation Reform Act, Intellectual property, COVID-19, Regeneron Pharmaceuticals, Physiology, European Medicines Agency, Food, U.S. Securities and Exchange Commission, Drug development, RNA, Biology, Risk, Patient, Nobel Prize in Physiology or Medicine, RNA interference, Diet, Government, Polyneuropathy, LDL, SEC, ESC, Science, Goal, Marketing, Instagram, Therapy, Central nervous system, Safety, Security (finance), RNA transfection, Medication, Novartis, Nasdaq, FDA, Blackstone, Growth, ORION, EMA, Gene silencing, Pharmaceutical industry, Alnylam Pharmaceuticals, Medicine, Inclisiran

Leqvio is the fourth Alnylam-discovered medicine using its RNAi therapeutic platform to be approved to date.

Key Points: 
  • Leqvio is the fourth Alnylam-discovered medicine using its RNAi therapeutic platform to be approved to date.
  • The Leqvio approval marks the first U.S. approval of an RNAi therapeutic indicated to treat a major risk factor for a highly prevalent disease.
  • Alnylam launched its first RNAi therapeutic in 2018 with the FDA approval of ONPATTRO (patisiran) for treatment of the polyneuropathy caused by hATTR amyloidosis, a progressive and life-threatening, rare, genetic disease.
  • The approval of Leqvio, a potentially transformational medicine for lowering LDL-C is a historic event for Alnylam and its RNAi therapeutics platform.

Regeneron Announces Presentation at the 40th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, December 22, 2021
Conference, Drug development, Homegrown, Medicine, Patient, Pain, Inflammation, Eye, Infection, Degenerative disease, Regeneron Pharmaceuticals, Twitter, NASDAQ, Biotechnology, Cancer, Allergy, Antibody, Lists of diseases, Laboratory, Science, FDA, Pharmaceutical industry

TARRYTOWN, N.Y., Dec. 22, 2021 /PRNewswire/ --Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022.

Key Points: 
  • TARRYTOWN, N.Y., Dec. 22, 2021 /PRNewswire/ --Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022.
  • The presentation is scheduled for 10:30 a.m. Eastern Time and may be accessed from the "Investors & Media" page of Regeneron's website at http://investor.regeneron.com/events-and-presentations .
  • An archived version of the presentation will be available for at least 30 days.
  • For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY® to Help Meet Continued Need for Vaccine Supply

Retrieved on: 
Monday, December 20, 2021
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Twitter, Regeneron Pharmaceuticals, Clinical trial, BNT162, Pierre Geneves, Publication, Awareness, RNA transfection, Annual report, Emergency Use Authorization, LinkedIn, Marketing, COVID-19, BioNTech, Pfizer–BioNTech COVID-19 vaccine, Infection, Vaccine, YouTube, European Commission, Safety, Research, Risk, Private Securities Litigation Reform Act, Royal commission, Program, Elanco, U.S. Securities and Exchange Commission, Peer review, News, Company, SEC, Hoffmann-La Roche, Cancer, Omicron, Immunotherapy, Science, Facebook, Pharmaceutical industry, Genentech, Pfizer, Pfizer: Breakthroughs That Change Patients’ Lives, BioNTech, PFIZER: BREAKTHROUGHS THAT CHANGE PATIENTS’ LIVES, BIONTECH

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Key Points: 
  • Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
  • For more than 170 years, we have worked to make a difference for all who rely on us.
  • We routinely post information that may be important to investors on our website at www.Pfizer.com .
  • This press release contains forward-looking statements of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.

Intellia Therapeutics Appoints Derek Hicks as Chief Business Officer

Retrieved on: 
Monday, December 20, 2021
Organization, Therapy, Spark Therapeutics, U.S. Securities and Exchange Commission, CRISPR, University, Intellia Therapeutics, Business, Genome, Private Securities Litigation Reform Act, Degenerative disease, Corporate development, Cancer, Cas9, NASDAQ, Risk, Regeneron Pharmaceuticals, Annual report, Form 10-K, Biotechnology, Pfizer, Patient, Tissue, Leadership, Achievement, Security (finance), MBA, NTLA, GLOBE, Twitter, Partnership, Head, Pharmaceutical industry, Management, Spark

CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the appointment of Derek Hicks to a newly created position as Executive Vice President, Chief Business Officer.

Key Points: 
  • CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the appointment of Derek Hicks to a newly created position as Executive Vice President, Chief Business Officer.
  • Mr. Hicks joins Intellia with more than 25 years of combined business, leadership and biotechnology experience, having most recently served as Head of Business Development at Spark Therapeutics.
  • I am thrilled to welcome Derek to Intellias executive team as we enter the next chapter in our evolution, said Intellia President and Chief Executive Officer John Leonard, M.D.
  • Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics using CRISPR/Cas9 technology.

Alnylam Submits CTA Application for ALN-XDH, an Investigational RNAi Therapeutic for the Treatment of Gout

Retrieved on: 
Monday, December 20, 2021
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, Intellectual property, Biology, Gout, Private Securities Litigation Reform Act, Risk, RNA interference, Medication, Disease, Therapy, Physiology, Instagram, LinkedIn, RNA, RNA transfection, FDA, Pain, CTA, Therapeutic index, Inflammatory arthritis, Uric acid, Growth, Nobel Prize in Physiology or Medicine, Medicines and Healthcare products Regulatory Agency, EMA, U.S. Securities and Exchange Commission, United Kingdom, Xanthine dehydrogenase, MHRA, Edema, Safety, Security (finance), Drug development, Flare, Chronic kidney disease, Sanofi, Alnylam Pharmaceuticals, Kidney, Tophus, Cell, Program, Nasdaq, Science, COVID-19, Enhance, SEC, Marketing, Twitter, Nobel Prize, Government, Company, XDH, CNS, Regeneron Pharmaceuticals, Gene silencing, Novartis, Patient, Sirna, Central nervous system, Joint, Pharmaceutical industry, Vaccine, Medicine, ALN-XDH, Gout, RNAi, Alnylam Pharmaceuticals, ALN-XDH, Gout, RNAI, ALNYLAM PHARMACEUTICALS

We believe the existing treatment landscape for gout has substantial limitations attributed to an incomplete response to standard of care, tolerability issues, and poor patient convenience.

Key Points: 
  • We believe the existing treatment landscape for gout has substantial limitations attributed to an incomplete response to standard of care, tolerability issues, and poor patient convenience.
  • ALN-XDH is an investigational, subcutaneously administered RNAi therapeutic targeting xanthine dehydrogenase (XDH) in development for the treatment of gout.
  • Reducing XDH with an RNAi therapeutic is expected to result in potent urate lowering, essential in preventing gout-associated flares and managing the disease.
  • Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform.

Onconova Therapeutics Appoints Adar Makovski Silverstein, Ph.D., as Director, Corporate Development

Retrieved on: 
Monday, December 13, 2021
Therapy, External, Company, Bar-Ilan University, Securities Act of 1933, Securities Exchange Act of 1934, Private Securities Litigation Reform Act, Corporate development, Business development, Cancer, City of Hope National Medical Center, Annual report, NASDAQ, Doctor of Philosophy, City, Regeneron Pharmaceuticals, Patient, Associate, Terminology, Nivolumab, Risk, GLOBE, Pharmaceutical industry, Hope, Biotechnology, Amgen

NEWTOWN, Pa., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Dr. Adar Makovski Silverstein has joined Onconova as Director, Corporate Development.

Key Points: 
  • NEWTOWN, Pa., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Dr. Adar Makovski Silverstein has joined Onconova as Director, Corporate Development.
  • Dr. Makovski Silverstein joins Onconova from Amgen, where she worked as Sr.
  • At Amgen, Dr. Makovski Silverstein was responsible for evaluating external scientific opportunities across all therapeutic areas and managing processes within business development and cross functional teams.
  • Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer.

Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema

Retrieved on: 
Monday, December 13, 2021
Nobel Prize, Therapy, U.S. Securities and Exchange Commission, CRISPR, Cas9, KLKB1, Clinical trial, Intellia Therapeutics, Prekallikrein, Hereditary angioedema, Private Securities Litigation Reform Act, Degenerative disease, IND, HAE, Genetic disorder, SC, Cancer, NASDAQ, Pharmacokinetics, Risk, Regeneron Pharmaceuticals, Liver, Form 10-Q, Safety, Tissue, Security (finance), COVID-19, Plasma kallikrein, NTLA, GLOBE, Twitter, Trial of the century, Pharmaceutical industry, Vaccine

Intellias multi-national Phase 1/2 study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of NTLA-2002 in adults with Type I or Type II hereditary angioedema (HAE).

Key Points: 
  • Intellias multi-national Phase 1/2 study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of NTLA-2002 in adults with Type I or Type II hereditary angioedema (HAE).
  • This includes the measurement of kallikrein protein levels and activity as determined by HAE attack rate measures.
  • This Phase 1/2 study will identify the dose of NTLA-2002 for use in future studies.Visit clinicaltrials.gov (NCT05120830) for more details.
  • Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics using CRISPR/Cas9 technology.

PharmaJet Partner Nykode Therapeutics Announces Phase 1/2 Clinical Trial With Next Generation DNA-Based COVID-19 Vaccine Candidates

Retrieved on: 
Tuesday, December 14, 2021
Biotechnology, Pharmaceutical, Health, FDA, Medical Devices, Infectious Diseases, Clinical Trials, Other Health, Therapy, LinkedIn, Injection, Genentech, Company, Clinical trial, RBD, Severe acute respiratory syndrome coronavirus 2, COVID-19, Cancer, Review, Vaccine, System, Regeneron Pharmaceuticals, CEO, Adaptation, Disease, Infection, CE marking, WHO, Nektar Therapeutics, Use, PQS, Roche, U.S. FDA, Certification, B cell, PharmaJet, Nykode Therapeutics, PHARMAJET, NYKODE THERAPEUTICS

PharmaJet , the maker of innovative, needle-free injection technology, today announced that one of its pharmaceutical partners, Nykode Therapeutics (formerly Vaccibody) has begun a phase 1/2 clinical trial to specifically address emerging SARS-CoV-2 variants.

Key Points: 
  • PharmaJet , the maker of innovative, needle-free injection technology, today announced that one of its pharmaceutical partners, Nykode Therapeutics (formerly Vaccibody) has begun a phase 1/2 clinical trial to specifically address emerging SARS-CoV-2 variants.
  • The DNA-based vaccines will be delivered intramuscularly in the clinical trial exclusively using the PharmaJet Stratis Needle-free Injection System.
  • We are pleased that Nykode Therapeutics is moving into clinical trials with their DNA-based COVID-19 vaccines using our PharmaJet Needle-free Injection System, commented Chris Cappello, President and CEO, PharmaJet.
  • PharmaJet Needle-free Systems provide increased vaccine effectiveness, a preferred patient and caregiver experience, and a proven path to commercialization.

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older

Retrieved on: 
Thursday, December 9, 2021
Health, FDA, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, U.S. Securities and Exchange Commission, Twitter, Risk, Awareness, Company, Research, Elanco, SEC, Immunotherapy, YouTube, Regeneron Pharmaceuticals, Publication, BNT162, Infection, Peer review, Safety, Private Securities Litigation Reform Act, RNA transfection, Vaccine, Cancer, BLA, Emergency Use Authorization, BioNTech, Science, Pierre Geneves, Pfizer–BioNTech COVID-19 vaccine, COVID-19, Program, Clinical trial, FDA, Facebook, LinkedIn, Marketing, Hoffmann-La Roche, News, Annual report, Pharmaceutical industry

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Key Points: 
  • Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
  • For more than 170 years, we have worked to make a difference for all who rely on us.
  • We routinely post information that may be important to investors on our website at www.Pfizer.com .
  • This press release contains forward-looking statements of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.